This is a story about the journey of commercialization for BMS' first cell therapies approved for the treatment of blood cancer. Jason 'Jake' Treese, played a critical role in the development, approval and commercialization of Abecma and Breyanzi; two cell therapies which have now treated 4,700 patients in clinical and commercial settings - patients that are often on their last line of treatment, and last hope of a successful treatment. We discuss leading the quality function in CAR-T cell therapy, the challenges faced in gaining approval for these therapies, the background of CAR-T cell therapy, the importance of building a strong team, the setbacks encountered during the approval process, and the motivation and inspiration behind the work.  Understanding CAR-T Cell TherapyLeading the Quality Function in CAR-T Cell TherapyBuilding the Team and Planning for SuccessChallenges and Setbacks in the Approval ProcessMaintaining Motivation and MissionThe Approval and ReflectionsAdvice for Quality Leaders in Cell TherapyConsiderations for the IndustryReflections on the Impact of Cell Therapy It's an incredible, emotional, and highly insightful story. For anyone that is leading an organisation through clinical development, particularly within cell therapy, this is a must listen!